Inflammatory Bowel Disease: Genetics, Epigenetics, and Pathogenesis

Italia Loddo, Claudio Romano, Italia Loddo, Claudio Romano

Abstract

Inflammatory bowel diseases (IBDs) are complex, multifactorial disorders characterized by chronic relapsing intestinal inflammation. Although etiology remains largely unknown, recent research has suggested that genetic factors, environment, microbiota, and immune response are involved in the pathogenesis. Epidemiological evidence for a genetic contribution is defined: 15% of patients with Crohn's Disease (CD) have an affected family member with IBD, and twin studies for CD have shown 50% concordance in monozygotic twins compared to <10% in dizygotics. The most recent and largest genetic association studies, which employed genome-wide association data for over 75,000 patients and controls, identified 163 susceptibility loci for IBD. More recently, a trans-ethnic analysis, including over 20,000 individuals, identified an additional 38 new IBD loci. Although most cases are correlated with polygenic contribution toward genetic susceptibility, there is a spectrum of rare genetic disorders that can contribute to early-onset IBD (before 5 years) or very early onset IBD (before 2 years). Genetic variants that cause these disorders have a wide effect on gene function. These variants are so rare in allele frequency that the genetic signals are not detected in genome-wide association studies of patients with IBD. With recent advances in sequencing techniques, ~50 genetic disorders have been identified and associated with IBD-like immunopathology. Monogenic defects have been found to alter intestinal immune homeostasis through many mechanisms. Candidate gene resequencing should be carried out in early-onset patients in clinical practice. The evidence that genetic factors contribute in small part to disease pathogenesis confirms the important role of microbial and environmental factors. Epigenetic factors can mediate interactions between environment and genome. Epigenetic mechanisms could affect development and progression of IBD. Epigenomics is an emerging field, and future studies could provide new insight into the pathogenesis of IBD.

Keywords: Crohn’s disease; IBD; early-onset IBD; epigenetics; genetics; inflammatory bowel disease.

Figures

Figure 1
Figure 1
The complex pathogenesis of inflammatory bowel diseases.

References

    1. Ventham NT, Kennedy NA, Nimmo ER, Satsangi G. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology (2013) 145:293–308.10.1053/j.gastro.2013.05.050
    1. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology (2011) 140:1704–12.10.1053/j.gastro.2011.02.046
    1. Uhlig HH, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology (2014) 147(5):990–1007.10.1053/j.gastro.2014.07.023
    1. Yi-Zhen Z, Yong-Yu L. Inflammatory bowel disease: pathogenesis. World J Gastroenterol (2014) 20(1):91–9.10.3748/wjg.v20.i1.91
    1. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet (2006) 367(9518):1271–84.10.1016/S0140-6736(06)68345-1
    1. Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med (2010) 16:90–7.10.1038/nm.2069
    1. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet (2012) 380:1590–605.10.1016/S0140-6736(12)60026-9
    1. Liu JZ, Van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet (2015) 47(9):979–86.10.1038/ng.3359
    1. McGovern D, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology (2015) 149(5):1163–76.10.1053/j.gastro.2015.08.001
    1. Uhlig HH. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease. Gut (2013) 62:1795–805.10.1136/gutjnl-2012-303956
    1. Xavier RJ, Rioux JD. Genome-wide association studies: a new window into immune-mediated diseases. Nat Rev Immunol (2008) 8:631–43.10.1038/nri2361
    1. Pigneur B, Escher J, Elawad M, Lima R, Buderus S, Kierkus J, et al. Phenotypic characterization of very early-onset IBD due to mutations in the IL10, IL10 receptor alpha or beta gene: a survey of the GENIUS Working Group. Inflamm Bowel Dis (2013) 19:2820–8.10.1097/01.MIB.0000435439.22484.d3
    1. Glocker EO, Frede N, Perro M, Sebire N, Elawad M, Shah N, et al. Infant colitis – it’s in the genes. Lancet (2010) 376:1272.10.1016/S0140-6736(10)61008-2
    1. Shouval DS, Ouahed J, Biswas A, Goettel JA, Horwitz BH, Klein C, et al. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol (2014) 122:177–210.10.1016/B978-0-12-800267-4.00005-5
    1. Iglesias A, Anyane-Yeboa K, Wynn J, Wilson A, Truitt Cho M, Guzman E, et al. The usefulness of whole-exome sequencing in routine clinical practice. Genet Med (2014) 16(12):922–31.10.1038/gim.2014.58
    1. Gilissen C, Hoischen A, Brunner HG, Veltman JA. Unlocking Mendelian disease using exome sequencing. Genome Biol (2011) 12:228.10.1186/gb-2011-12-9-228
    1. Gilissen C, Hoischen A, Brunner HG, Veltman JA. Disease gene identification strategies for exome sequencing. Eur J Hum Genet (2012) 20(5):490–7.10.1038/ejhg.2011.258
    1. Shashi V, McConkie-Rosell A, Schoch K, Kasturi V, Rehder C, Jiang YH, et al. Practical considerations in the clinical application of whole-exome sequencing. Clin Genet (2015).10.1111/cge.12569
    1. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med (2011) 13:255–62.10.1097/GIM.0b013e3182088158
    1. Joo MY, Tae OK. Epigenetic alterations in inflammatory bowel disease and cancer. Intest Res (2015) 13(2):112–21.10.5217/ir.2015.13.2.112
    1. Ventham NT, Kennedy NA, Quintana JF, Nimmo ER, Buck AH, Satsangi J. MicroRNAs: new players in IBD. Gut (2015) 64(3):504–17.10.1136/gutjnl-2014-307891
    1. Saini HK, Griffiths-Jones S, Enright AJ. Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A (2007) 104(45):17719–24.10.1073/pnas.0703890104
    1. Coskun M, Bjerrum JT, Seidelin JB, Nielsen OH. MicroRNAs in inflammatory bowel disease – pathogenesis, diagnostics and therapeutics. World J Gastroenterol (2012) 18:4629–34.10.3748/wjg.v18.i34.4629
    1. Iborra M, Bernuzzi F, Invernizzi P, Danese S. MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response. Autoimmun Rev (2012) 11:305–14.10.1016/j.autrev.2010.07.002
    1. Jensen MD, Andersen RF, Christensen H, Nathan T, Kjeldsen J, Madsen JS. Circulating microRNAs as biomarkers of adult Crohn’s disease. Eur J Gastroenterol Hepatol (2015) 27(9):1038–44.10.1097/MEG.0000000000000430
    1. Chapman CG, Pekow J. The emerging role of miRNAs in inflammatory bowel disease: a review. Therap Adv Gastroenterol (2015) 8(1):4–22.10.1177/1756283X14547360
    1. Dalal SR, Kwon JH. The role of microRNA in inflammatory bowel disease. Gastroenterol Hepatol (2010) 6(11):714–22.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe